COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
OncoMyx develops myxoma-virus-based oncolytic immunotherapies, engineering multi-armed dsDNA poxviruses that express antitumor immunomodulators for systemic IV, repeat dosing and combination with checkpoint inhibitors.
